MA50066A - Compositions à usage topique pour le traitement de la leishmaniose cutanée - Google Patents
Compositions à usage topique pour le traitement de la leishmaniose cutanéeInfo
- Publication number
- MA50066A MA50066A MA050066A MA50066A MA50066A MA 50066 A MA50066 A MA 50066A MA 050066 A MA050066 A MA 050066A MA 50066 A MA50066 A MA 50066A MA 50066 A MA50066 A MA 50066A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- treatment
- topical use
- leishmaniasis
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17306143.3A EP3449906A1 (fr) | 2017-09-04 | 2017-09-04 | Composition topique à utiliser dans le traitement de la leishmaniose cutanée |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50066A true MA50066A (fr) | 2021-05-26 |
Family
ID=59955514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050066A MA50066A (fr) | 2017-09-04 | 2018-09-03 | Compositions à usage topique pour le traitement de la leishmaniose cutanée |
Country Status (9)
Country | Link |
---|---|
US (1) | US11351146B2 (fr) |
EP (2) | EP3449906A1 (fr) |
CN (1) | CN111148516A (fr) |
BR (1) | BR112020004337A2 (fr) |
CO (1) | CO2020003486A2 (fr) |
IL (1) | IL272999A (fr) |
MA (1) | MA50066A (fr) |
MX (1) | MX2020002358A (fr) |
WO (1) | WO2019043212A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019025606A1 (fr) * | 2017-08-03 | 2019-02-07 | Bionoox Sa | Compositions destinées à être utilisées pour le traitement de la leishmaniose cutanée |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2835253B1 (fr) | 2002-01-31 | 2008-02-01 | Pape Patrice Le | Composes, en particulier de derives urees ou esters de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires |
-
2017
- 2017-09-04 EP EP17306143.3A patent/EP3449906A1/fr not_active Withdrawn
-
2018
- 2018-09-03 WO PCT/EP2018/073576 patent/WO2019043212A1/fr unknown
- 2018-09-03 MX MX2020002358A patent/MX2020002358A/es unknown
- 2018-09-03 EP EP18759341.3A patent/EP3678656A1/fr not_active Withdrawn
- 2018-09-03 CN CN201880061769.0A patent/CN111148516A/zh active Pending
- 2018-09-03 BR BR112020004337-0A patent/BR112020004337A2/pt unknown
- 2018-09-03 MA MA050066A patent/MA50066A/fr unknown
- 2018-09-03 US US16/644,278 patent/US11351146B2/en active Active
-
2020
- 2020-03-01 IL IL272999A patent/IL272999A/en unknown
- 2020-03-25 CO CONC2020/0003486A patent/CO2020003486A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3449906A1 (fr) | 2019-03-06 |
US11351146B2 (en) | 2022-06-07 |
BR112020004337A2 (pt) | 2020-09-08 |
EP3678656A1 (fr) | 2020-07-15 |
WO2019043212A1 (fr) | 2019-03-07 |
MX2020002358A (es) | 2020-11-09 |
CN111148516A (zh) | 2020-05-12 |
IL272999A (en) | 2020-04-30 |
US20210059979A1 (en) | 2021-03-04 |
CO2020003486A2 (es) | 2020-07-31 |
WO2019043212A8 (fr) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
MA47820A (fr) | Traitement de la glycogénose de type iii | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA51738A (fr) | Composés pour le traitement de la douleur | |
MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
IL278949A (en) | Benzene sulfonamide compounds and their use as medicinal agents | |
GB2586731B (en) | Topical skin care compositions | |
MA41629A (fr) | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité | |
MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
FR3015285B1 (fr) | Formulation pour le traitement des cheveux |